Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 6Neoplasm Metastasis 5Neoplasms 4Triple Negative Breast Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Sarcoma 2Rectal Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Lung Cancer - Malignant Pleural Mesothelioma 1Liver Neoplasms 1Leukemia 1Hematologic Neoplasms 1Hemangiosarcoma 1Gastrointestinal Stromal Tumors 1

Interventions

Cyclophosphamide 64Peripheral Blood Stem Cell Transplantation 58fludarabine phosphate 55Busulfan 44Tacrolimus 39Methotrexate 38Cytarabine 37Filgrastim 34Mycophenolic Acid 33Cyclosporine 33Antilymphocyte Serum 32Whole-Body Irradiation 28Radiotherapy 25Methylprednisolone 22Imatinib Mesylate 22Etoposide 22Melphalan 18Cord Blood Stem Cell Transplantation 18Flow Cytometry 14Thiotepa 12Dasatinib 12Therapeutics 11sargramostim 10merphos 10fludarabine 10Sirolimus 10Granulocyte Colony-Stimulating Factor 10nilotinib 9Prednisone 9Decitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × STA 9090 × Clear all
NCT00964873 2014-09-18

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Synta Pharmaceuticals Corp.

Phase 1 Completed
29 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡